What is the EPS estimate for Milestone Pharmaceuticals Inc's next earnings report?

The consensus EPS estimate for Milestone Pharmaceuticals Inc's Q3 2026 earnings report is -0.22. Analysts expect revenue of 1.14M.

How did Milestone Pharmaceuticals Inc perform in its last earnings report?

On 2026-08-12, Milestone Pharmaceuticals Inc reported EPS of -0.21 and -3.15% EPS surprise. Revenue was 559.00K, compared with the consensus estimate of 1.14M.

What does an earnings surprise mean?

An earnings surprise is the difference between a company's reported EPS or revenue and the analysts' consensus estimate. A positive surprise means results exceeded expectations, while a negative surprise means results fell short.

How can earnings reports affect MIST stock?

Earnings reports can increase volatility in MIST stock, especially when reported EPS, revenue or company guidance differs from market expectations. An earnings beat does not always lead to a price increase, as investors also consider the outlook, valuation and broader market conditions.

Milestone Pharmaceuticals Inc Earnings Dates & Reports

This page offers detailed Milestone Pharmaceuticals Inc earnings data including the latest Milestone Pharmaceuticals Inc earnings report, the upcoming Milestone Pharmaceuticals Inc earnings date, historical data and Milestone Pharmaceuticals Inc earnings call news.

MIST Latest Quarter’s Earnings

Announce Date8/12/2026

EPS Actual (USD)-0.21

Revenue Actual (USD)559.00K

MIST Upcoming Quarter's Earnings

Announce Date11/13/2026(Pre-Market)

EPS Forecast (USD)-0.22

Revenue Forecast (USD)1.14M

MIST FY2025 Earnings

EPS (YoY)-0.75-12.64%

Revenue (YoY)1.55M--

Milestone Pharmaceuticals Inc (MIST) Earnings History

Release Date	Period End	EPS/Forecast	Revenue/Forecast	EPS Surprise %	Revenue Surprise %
8/12/2026	06/2026	-0.21/-0.20	559.00K/816.67K	-5.80%	-31.55%
5/13/2026	03/2026	-0.20/0.31	238.00K/37.65M	-165.24%	-99.37%
3/20/2026	12/2025	-0.16/-0.16	1.55M/0.00	-2.61%	--
11/12/2025	09/2025	-0.12/-0.16	0.00/0.00	24.66%	--
8/12/2025	06/2025	-0.20/-0.18	0.00/0.00	-10.05%	--
5/14/2025	03/2025	-0.39/-0.18	0.00/0.00	-109.90%	--
3/13/2025	12/2024	-0.19/-0.15	0.00/0.00	-22.33%	--
11/12/2024	09/2024	-0.14/-0.16	0.00/0.00	12.69%	--

Milestone Pharmaceuticals Inc Latest Earnings Call Transcripts

Milestone Pharmaceuticals (MIST) Q2 2026 Earnings Call: CARDAMYST Coverage Tops 50%

Milestone Pharmaceuticals' Q2 2026 earnings call covered $0.6 million in CARDAMYST revenue, coverage above 50%, launch spending and the ReVeRA-301 trial.